TOPページ
|
英語
日本語
|
CONNECT WITH US:
ホーム
JCNについて
サービス
お問い合わせ
会員企業ログイン
ホーム
プレスリリース一覧
China Medical System Holdings Ltd.
プレスリリース一覧
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10
Jan 24, 2025 23:00 JST
More info..
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 09, 2025 09:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type.
More info..
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
Dec 09, 2024 14:00 JST
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
More info..
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
Dec 02, 2024 22:30 JST
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
More info..
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
Sep 24, 2024 22:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023
Aug 16, 2024 14:00 JST
On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023.
More info..
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
Aug 05, 2024 23:00 JST
China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA).
More info..
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00 JST
In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development.
More info..
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
Jun 25, 2024 21:46 JST
On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China.
More info..
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
Jun 18, 2024 19:53 JST
More info..
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
Apr 23, 2024 23:06 JST
More info..
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Apr 01, 2024 21:30 JST
More info..
China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs
Mar 28, 2024 11:29 JST
More info..
China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R)
Feb 04, 2024 10:00 JST
More info..
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA
Jan 02, 2024 15:00 JST
More info..
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL
Dec 13, 2023 18:36 JST
More info..
China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug
Aug 24, 2023 21:00 JST
More info..
China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 21:00 JST
Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..
China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China
Jun 12, 2023 21:00 JST
More info..
China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST
On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..
CMS Releases Its 2022 Interim Report, Achieves Sustained Growth with Its Platform Strategy
Aug 26, 2022 19:00 JST
More info..
1
新着プレスリリース
Hola Prime Plans to Enter Futures Trading to Solve One of Finance's Most Persistent Problems: Complexity
2025年05月23日 20時00分
sureWin Nominated for Best iGaming Platform 2025 in SiGMA Awards
2025年05月23日 19時00分
三菱商事、経営戦略2027の実現に向けた人事領域の取り組みについて発表
2025年05月23日 14時00分
東海国立大学機構と富士通、生成AIを用いた診療データの活用により治験候補患者の選定に貢献
2025年05月23日 10時30分
トヨタグループ5社、AI・ソフトウェアの人財育成とイノベーションを加速
2025年05月22日 14時00分
Honda 二輪車の世界生産累計5億台を達成
2025年05月22日 14時00分
防災科研、富士通、衛星データサービス企画、三菱電機が「日本版災害チャータ」実運用スキーム高度化に向けた共同研究契約を締結
2025年05月22日 12時00分
三菱重工とヤマハ発動機、ハイブリッドタイプ中型無人機の飛行試験を実施
2025年05月22日 10時30分
PlayX Showcases AI-Powered Transparency and Fairness at SiGMA Asia 2025 in Manila
2025年05月21日 22時00分
米国株式投資の「新定番」ついに登場 インデックスファンドの次なる選択肢へ 米国株式アクティブ残高9年連続世界No.1ティー・ロウ・プライス[1]
2025年05月21日 16時00分
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の製品・開発品に関する発表
2025年05月21日 09時00分
三菱重工、「デジタルトランスフォーメーション(DX)銘柄2025」に選定
2025年05月20日 12時00分
AI Generated Books Unveils the Lucky Trigger: A Groundbreaking AI-Generated Spy Thriller
2025年05月20日 10時19分
Suzhou Hosts First Bai Juyi Poetry Conference in Anhui, China
2025年05月19日 21時40分
PaySaxas Secures EMI License and Appoints Dmitrii Barbasura as CEO, Ushering in a New Era of Growth
2025年05月19日 15時00分
Honda、「ZR-V」を一部改良して発売
2025年05月19日 11時14分
三菱重工、環境に配慮した次世代新交通システムの新ブランド「Prismo」を開発、市場投入
2025年05月19日 11時06分
Spiritual Business Guide 'Zen and Stilettos' Sells 100,000 Copies, Enters Publisher's Top-10
2025年05月16日 08時00分
Hola Prime and Pro Basketball Player Karl-Anthony Towns Team up for 'Speed is Success' Campaign, Redefining Prop Trading
2025年05月14日 23時00分
African Mining Giant Intends to List in Hong Kong to Build West African Gold Leader
2025年05月13日 19時25分
もっと見る >>